Dosing Begins in Canada for Phase 1/2 Trial of GTX-102 in Children

Dosing Begins in Canada for Phase 1/2 Trial of GTX-102 in Children

311088

Dosing Begins in Canada for Phase 1/2 Trial of GTX-102 in Children

The first patient has been dosed in Canada as part of a Phase 1/2 clinical trial of the investigational therapy GTX-102 in children and adolescents with Angelman syndrome. The open-label KIK-AS trial (NCT04259281), which is also underway in the U.S. and U.K., has enrolled three other patients who are scheduled to begin dosing, according to a press release from GeneTx Biotherapeutics and Ultragenyx Pharmaceutical, the therapy co-developers. The trial aims to enroll up to 20 pediatric patients (ages 4 to 17)…

You must be logged in to read/download the full post.